- Ready-to-use kit expands range of bioanalysis kits, and enables generic detection of immune complexes in cyno samples
Uppsala, Sweden, 02 May 2023: Gyros Protein Technologies AB, a leading provider of peptide synthesizers and reagents and a pioneer in automated nanoliter-scale immunoassays, today announced the introduction of Gyrolab® Generic Cyno Anti-Drug Antibodies (ADA) Kit Reagents, for the detection of circulating immune complexes of human IgG with cyno anti-human IgG. The new ready-to-use kit reagents streamline pre-clinical development of antibody-based therapeutics, enabling immunogenicity screening of drug candidates without the need for drug-specific ADA assay development.
The new kit expedites bioanalysis by removing the need for assay development and optimization across molecules to provide robust, reproducible, reliable data from nanoliter sample volumes. This is beneficial when ADA assessment is evaluated in pre-clinical animal models where sample volume may be limited.
Detecting and monitoring ADA is essential throughout drug development, in particular during the discovery stage, where multiple early-stage candidates are evaluated in parallel. During non-clinical studies, ADA monitoring is critical in understanding unexpected clearance profiles and safety or efficacy issues caused by formation of immune complexes.
The new bioanalysis kit is optimized for use on all Gyrolab systems and complements the Company’s existing portfolio of ready-to-use kits and solutions for pharmacokinetics and toxicokinetics, while expanding the utility of the Gyrolab platform into drug screening and preclinical phases of development. Automation with Gyrolab systems reduces variability due to manual intervention and speeds up workflows by generating 96 data points within 80 minutes, helping to speed the development of novel therapeutics. Additionally, the Gyrolab platform supports the development of drug-specific ADA assays in the later stages of drug development, using automated acid dissociation in the Gyrolab Mixing CD 96 and the dedicated Gyrolab ADA Software, enabling immunogenicity assessment all the way from discovery to every phase of process development.
Mark Vossenaar, General Manager, Biopharmaceutical Development Division, Gyros Protein Technologies, commented: “The introduction of the Gyrolab Generic Cyno ADA Kit Reagents is another valuable addition to our extensive portfolio of ready-to-use kits and solutions. Expanding the utility of our platform into drug screening and preclinical development will enable researchers to maximize performance and productivity, which will ultimately reduce the time neded to develop novel antibody-based therapies.”
For more information: www.gyrosproteintechnologies.com/immunoassays/products/gyrolab-generic-cyno-ada-kit-reagents
Notes to editors
For a high-resolution image please contact Zyme Communications.
Dr Ben Rutter
Zyme Communications:
Tel: +44 (0) 7920 770 935
Email: ben.rutter@zymecommunications.com
Mark Vossenaar
Gyros Protein Technologies
Tel: +31 6 34735894
Email: mark.vossenaar@gyrosproteintech.com
About Gyros Protein Technologies https://www.gyrosproteintechnologies.com/
Gyros Protein Technologies enables bioanalytical solutions and peptide synthesis, helping scientists increase biomolecule performance and productivity in research, drug discovery, pre-clinical and clinical development, and bioprocess applications. Proprietary high performance nanoliter-scale immunoassay platforms, Gyrolab® xPand, and Gyrolab xPlore™, and Gyrolab immunoassay kits are used by scientists at leading pharmaceutical, biotech, CRO, and CMO companies in the development and manufacturing of various biotherapies including those based on peptides, antibodies, cell and gene therapies and vaccines. Gyrolab immunoassays provide key workflow advantages of speed, automation, and low reagent usage, and assay quality advantages of wide dynamic range with robust precision and reproducibility in applications including pharmacokinetics/pharmacodynamics, immunogenicity, and analysis of bioprocess-related impurities. Our low to mid-scale peptide synthesizer platforms, PurePep® Chorus, Symphony® X, and PurePep® Sonata+, and chemistries deliver uncompromising purity, flexibility, and quality synthesis for discovery and pre-clinical studies of simple to complex multifunctional peptides. Our peptide synthesis and bioanalytical solutions accelerate the discovery, development, and manufacturing of safer biotherapeutics. Gyros Protein Technologies is part of the Biopharmaceutical Development Division of Mesa Laboratories, Inc. (Nasdaq: MLAB).
Forward Looking Statements
This release contains “forward-looking statements” – that is, statements that relate to future, not past, events. In this context, forward-looking statements often address our expected future business and financial performance and financial condition, and often contain words such as “expect,” “assume,” “anticipate,” “intend,” “plan,” “believe,” “seek,” “see,” or “will.” Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include the duration and severity of the COVID-19 pandemic, expectations regarding our products, our ability to develop and market new or improved products, our ability to compete effectively, international legal and regulatory risks, and product quality and liability issues. For further information regarding our risks and uncertainties, please refer to the “Risk Factors” and “Management's Discussion and Analysis of Financial Condition and Results of Operation” in Mesa Laboratories, Inc.’s public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. We caution you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.